SynthesisEpidemiology and infection2006
Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.
Synthesis in Epidemiology and infection, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Population-based prevalence surveys during the Covid-19 pandemic: A systematic review.Reviews in medical virology · 2021Pooled it
- Pooled it
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses.Respiratory research · 2020Pooled it
- Sensitivity analysis of epidemic forecasting and spreading on networks with probability generating functions.Journal of the Royal Society, Interface · 2026Article
- Individual Immune Response to SARS-CoV-2 Infection-The Role of Seasonal Coronaviruses and Human Leukocyte Antigen.Biology · 2023Article
- Risk management and communication plans from SARS to COVID-19 and beyond.The International journal of health planning and management · 2022Review
- The COVID-19 pandemic - How many times were we warned before?European journal of internal medicine · 2022Review
- Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.The Journal of clinical investigation · 2021Article
- Coronavirus seroprevalence among villagers exposed to bats in Thailand.Zoonoses and public health · 2021Article
- Human Coronaviruses: Counteracting the Damage by Storm.Viruses · 2021Review
- Seroprevalence of human coronaviruses among patients visiting hospital-based sentinel sites in Uganda.BMC infectious diseases · 2021Article
- Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System.Public health reports (Washington, D.C. : 1974) · 2021Article
- Article
- High Seroprevalence of SARS-CoV-2 (COVID-19)-Specific Antibodies among Healthcare Workers: A Cross-Sectional Study in Guilan, Iran.Journal of environmental and public health · 2021Article
- How Useful is COVID-19 Antibody Testing - A Current Assessment for Oncologists.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2021Article
- SARS-CoV-2 infections in children and young people.Clinical immunology (Orlando, Fla.) · 2020Review
- BeyondJournal of the Royal Society, Interface · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.